undamentalytics Newsletter
Sign in

Revolution Medicines, Inc. income statement

In fiscal 2025, Revolution Medicines, Inc. reported revenue of $0 and net income of −$1.13bn, or −$5.95 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Revenue20504329351200
Research and development5192132187253423592987
General and administrative9122130417697195
Operating income−40−54−111−188−258−487−690−1,182
Interest expense000000024
Income before tax−42−52−109−187−249−440−601−1,131
Income tax—−4−00−0−4−10
Net income−42−48−108−187−249−436−600−1,131
Diluted EPS−$1.06−$1.12−$2.01−$2.57−$3.08−$3.86−$3.58−$5.95
Diluted shares (average)46m55m55m73m81m113m168m190m
EBITDA−39−52−108−185−254−482−683−1,175

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Revolution Medicines, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Revolution Medicines, Inc.